Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CATERPILLAR™ Arterial Embolization Device Study (CHRYSALIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04090320
Recruitment Status : Recruiting
First Posted : September 16, 2019
Last Update Posted : September 27, 2019
Sponsor:
Information provided by (Responsible Party):
C. R. Bard

Brief Summary:
The primary objective of this study is to evaluate the performance and safety of the CATERPILLAR™ Arterial Embolization Device when used for arterial embolization in the peripheral vasculature.

Condition or disease Intervention/treatment Phase
Embolization, Therapeutic Device: CATERPILLAR™ Arterial Embolization Device Not Applicable

Detailed Description:
This feasibility study is a prospective, multi-center, single-arm study of the CATERPILLAR™ Arterial Embolization Device. Up to twenty (20) subjects will be treated with the CATERPILLAR™ Arterial Embolization Device at up to 5 investigational sites in New Zealand and Australia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Multi-Center, Single-Arm Study Assessing the Clinical Use of the CATERPILLAR™ Arterial Embolization Device System for Arterial Embolization in the Peripheral Vasculature (CHRYSALIS)
Actual Study Start Date : September 25, 2019
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Arm Intervention/treatment
Experimental: CATERPILLAR™ Arterial Embolization Device
Placement of the CATERPILLAR™ Arterial Embolization Device via percutaneous transcatheter embolization (PTE).
Device: CATERPILLAR™ Arterial Embolization Device
Placement of the CATERPILLAR™ Arterial Embolization Device for patients requiring arterial embolization in the peripheral vasculature.
Other Names:
  • CATERPILLAR™ Micro (027)
  • CATERPILLAR™ (038 & 056)




Primary Outcome Measures :
  1. Technical Success [ Time Frame: Index Procedure. ]
    Technical Success: Successful occlusion of the target embolization site(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Technical success will be reported for each target embolization site.

  2. Freedom from Device-Related SAEs [ Time Frame: 30 (-7/+21) Days ]
    Freedom from Device-Related Serious Adverse Events (SAE) through 30 day follow-up.


Secondary Outcome Measures :
  1. Time Point of Occlusion [ Time Frame: Index Procedure ]
    The percentage of target embolization site(s) with occlusion at ≤1, ≤2, ≤3, ≤4, ≤5, ≤10 and >10 minutes post-treatment.

  2. Freedom from Recanalization [ Time Frame: 30 (-7/+21) Days ]
    Freedom from clinically relevant recanalization of the target embolization site(s) through 30 day follow-up as confirmed by the Investigator. Clinically relevant recanalization is defined as recanalization through the study device that requires a re-intervention. Freedom from recanalization will be reported for each target embolization site.

  3. Freedom from Migration [ Time Frame: 30 (-7/+21) Days ]

    Freedom from Migration will be reported for each study device as follows:

    • Freedom from clinically relevant acute migration of the study device(s) as confirmed by the Investigator via angiographic assessment during the Index Procedure. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires intervention.
    • Freedom from clinically relevant migration of the study device(s) through 30 day follow-up as confirmed by the Investigator. Clinically relevant migration is defined as migration of the study device from the target embolization site that requires a re-intervention.

  4. Freedom from Device and/or Procedure-Related Adverse Events [ Time Frame: 30 (-7/+21) Days ]
    Freedom from device and/or procedure-related adverse events (AE) through 30 day follow-up.

  5. Investigator Satisfaction [ Time Frame: Index Procedure ]

    The following will be reported by Investigators for each study device during the Index Procedure:

    • Accurate delivery of the CATERPILLAR™ Arterial Embolization Device to the target embolization site
    • Ease of CATERPILLAR™ Arterial Embolization Device trackability and deliverability
    • Acceptability of CATERPILLAR™ Arterial Embolization Device visibility under fluoroscopy



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Clinical Inclusion Criteria:

  1. Subject must voluntarily sign and date the approved Informed Consent Form (ICF) prior to collection of study data or performance of study procedures.
  2. Subject must be either male or non-pregnant female ≥18 years of age with an expected lifespan sufficient to allow for completion of all study procedures.
  3. Subject must be willing and able to comply with protocol requirements, including all study visits and procedures.
  4. Subject must require peripheral vascular occlusion at an arterial target embolization site(s) that can be treated with the CATERPILLAR™ Arterial Embolization Device according to the Instructions for Use (IFU). Note: More than one target embolization site may be treated per subject.

    Angiographic Inclusion Criteria:

  5. The target embolization site(s) must be located in a native arterial vessel(s) with the intended arterial vessel diameter ranges shown in the IFU, as assessed by the Investigator (via visual estimate).
  6. The target embolization site(s) must have a landing zone sufficient to accommodate the device implant lengths shown in the IFU.

Clinical Exclusion Criteria:

  1. The subject's access vessel(s) preclude safe insertion of the delivery catheter.
  2. The subject's target embolization site(s) is located within a vein.
  3. The subject's target embolization site(s) is located within the head, neck, heart or coronary vessels.
  4. The subject's target embolization site(s) is located across highly locomotive joints or muscle beds (e.g. elbow, hip, knee, shoulder, thoracic inlet/outlet).
  5. The subject's target embolization site(s) is located in a high-flow vessel where, in the opinion of the Investigator, there may be significant risk of migration and unintended (non-target site) occlusion.
  6. The subject has a known allergy or hypersensitivity to contrast media that cannot be adequately pre-medicated.
  7. The subject has a known allergy or hypersensitivity to any of the device materials including: cobalt, chromium, nickel, titanium, platinum, iridium, polyurethane or polyethylene.
  8. The subject will receive anticoagulant or antiplatelet therapy (e.g. direct thrombin inhibitors, factor Xa inhibitors, vitamin K antagonists) before, during and/or after treatment with the study device, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  9. The subject has a known uncontrolled blood coagulation or bleeding disorder.
  10. The subject has an unresolved systemic infection.
  11. The subject's required pre-operative laboratory tests and/or physical examination indicate abnormal results, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  12. The subject has a connective tissue disorders (e.g. Ehlers-Danlos Syndrome), arteritis (e.g. Takayasu's Disease) or another circulatory disorder, which, in the opinion of the Investigator, would clinically interfere with the study endpoints.
  13. The subject has another medical condition which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, may confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.
  14. The subject is currently participating in an investigational drug or another device study that has not completed the study treatment or that clinically interferes with the study endpoints. Note: Studies requiring extended follow-up visits for products that were investigational, but have since become commercially available, are not considered investigational studies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04090320


Contacts
Layout table for location contacts
Contact: David Stanfield (480) 350-6467 David.Stanfield@bd.com

Locations
Layout table for location information
Australia, New South Wales
Sydney Local Health District Not yet recruiting
Camperdown, New South Wales, Australia
Contact: Lisa Turner    61 2 9515 6366    Lisa.Turner@health.nsw.gov.au   
Principal Investigator: Steven Dubenec, FRACS         
Australia, Victoria
Alfred Health Not yet recruiting
Melbourne, Victoria, Australia
Contact: Helen Kavnoudias, Ph.D    61 3 9076 3606    h.kavnoudias@alfred.org.au   
Principal Investigator: Gerard Goh, FRANZCR         
New Zealand
Auckland Hospital Recruiting
Auckland, New Zealand
Contact: Elleni Takele    09 307 4949 ext 21976    ElleniT@adhb.govt.nz   
Principal Investigator: Andrew Holden, FRANZCR         
Clinical Trials New Zealand Not yet recruiting
Hamilton, New Zealand
Contact: Eileen Bisley    64 7 843 0105    eileen@clinicaltrialsnz.com   
Principal Investigator: Thodur Vasudevan, FRCS         
Sponsors and Collaborators
C. R. Bard
Investigators
Layout table for investigator information
Principal Investigator: Andrew Holden, FRANZCR Auckland City Hospital

Layout table for additonal information
Responsible Party: C. R. Bard
ClinicalTrials.gov Identifier: NCT04090320     History of Changes
Other Study ID Numbers: BPV-16-002
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: September 27, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by C. R. Bard:
Arterial Embolization
Vascular Plug